Loading...
Market
Xaira's next major innovation type by end of 2025
4
Resolution / Starting Odds
New drug delivery system • 20%
AI-driven diagnostic tool • 20%
Advanced biopharmaceutical therapy • 20%
Genetic editing technology • 20%
None • 20%
Xaira press releases and technology disclosures
Story
Xaira, Led by CEO Marc Tessier-Lavigne, Raises $1B for RFdiffusion Tech
Apr 25, 2024, 12:25 AM
Xaira, a new biotechnology company, has successfully raised over $1 billion in committed capital, marking one of the largest funding rounds in biotech history. The company, led by CEO Marc Tessier-Lavigne, is set to focus on next-generation technology in biopharma, leveraging AI and RFdiffusion from David Baker's lab. The funding round saw participation from major venture capital firms including Arch, Foresite, F-Prime, NEA, Sequoia, Lux, Lightspeed, and Two Sigma. This significant financial backing underscores the growing interest and investment in tech-driven biopharma solutions.
View original story
Similar markets
Oncology • 25%
Cardiovascular • 25%
Neurology • 25%
Immunology • 25%
Healthcare • 20%
Automotive • 20%
Finance • 20%
Retail • 20%
Energy • 20%
Healthcare • 25%
Automotive • 25%
Finance • 25%
Entertainment • 25%
Natural Language Processing • 33%
Machine Learning • 33%
Robotics • 33%
Chatbots • 25%
Autonomous vehicles • 25%
Healthcare AI • 25%
Other AI applications • 25%
Healthcare • 25%
Automotive • 25%
Finance • 25%
Entertainment • 25%
Under $30 billion • 25%
$30 billion to $50 billion • 25%
$50 billion to $70 billion • 25%
Over $70 billion • 25%
Under $30 billion • 25%
$30 billion to $50 billion • 25%
$50 billion to $70 billion • 25%
Over $70 billion • 25%